Optimizing clinical trial design for multiple system atrophy

Lessons from the rifampicin study

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by autonomic failure and parkinsonism/ataxia; no treatment exists to slow disease progression. A number of factors have prevented or compromised trials targeting disease modification. A major hurdle has been uncertainty about the number of patients needed to achieve adequate power. Information based on natural history studies suggested such numbers to be so large that only international multi-center models seemed feasible. When designing the rifampicin trial in MSA we sought to identify and apply strategies that would improve power and reduce the number needed to treat to allow for an oligocenter approach. Strategies included: (1) inclusion/exclusion criteria designed to enroll patients with relatively early, actively progressing disease; (2) minimizing dropouts; (3) pre-defined interim analysis; and (4) approaches to reduce scoring variability. The model allowed for the number needed to treat to be only 50 patients per treatment arm. Ten selected sites managed to reach the recruitment goal within 12 months. The dropout rate was less than 10 %, and the goal of enrolling patients with actively progressing disease was accomplished as reflected by the progression rate in the placebo group. Data from this unfortunately negative trial can now be effectively used to more realistically power future trials. A number of ways to further improve trial design and feasibility have been identified and include rigorous site selection and training, designated primary site investigators, improved error trapping, early site visits, remedial training, and future biomarkers for earlier diagnosis and tracking of disease progression.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalClinical Autonomic Research
Volume25
Issue number1
DOIs
StatePublished - Feb 1 2015

Fingerprint

Multiple System Atrophy
Rifampin
Clinical Trials
Numbers Needed To Treat
Disease Progression
Parkinsonian Disorders
Ataxia
Natural History
Neurodegenerative Diseases
Uncertainty
Early Diagnosis
Biomarkers
Placebos
Research Personnel
Therapeutics

Keywords

  • Multiple system atrophy
  • Rifampicin
  • Trial design

ASJC Scopus subject areas

  • Clinical Neurology
  • Endocrine and Autonomic Systems

Cite this

@article{98c7dac5dcfb41c0bd3b13d82ca16fa9,
title = "Optimizing clinical trial design for multiple system atrophy: Lessons from the rifampicin study",
abstract = "Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by autonomic failure and parkinsonism/ataxia; no treatment exists to slow disease progression. A number of factors have prevented or compromised trials targeting disease modification. A major hurdle has been uncertainty about the number of patients needed to achieve adequate power. Information based on natural history studies suggested such numbers to be so large that only international multi-center models seemed feasible. When designing the rifampicin trial in MSA we sought to identify and apply strategies that would improve power and reduce the number needed to treat to allow for an oligocenter approach. Strategies included: (1) inclusion/exclusion criteria designed to enroll patients with relatively early, actively progressing disease; (2) minimizing dropouts; (3) pre-defined interim analysis; and (4) approaches to reduce scoring variability. The model allowed for the number needed to treat to be only 50 patients per treatment arm. Ten selected sites managed to reach the recruitment goal within 12 months. The dropout rate was less than 10 {\%}, and the goal of enrolling patients with actively progressing disease was accomplished as reflected by the progression rate in the placebo group. Data from this unfortunately negative trial can now be effectively used to more realistically power future trials. A number of ways to further improve trial design and feasibility have been identified and include rigorous site selection and training, designated primary site investigators, improved error trapping, early site visits, remedial training, and future biomarkers for earlier diagnosis and tracking of disease progression.",
keywords = "Multiple system atrophy, Rifampicin, Trial design",
author = "Wolfgang Singer and Low, {Phillip Anson}",
year = "2015",
month = "2",
day = "1",
doi = "10.1007/s10286-015-0281-2",
language = "English (US)",
volume = "25",
pages = "47--52",
journal = "Clinical Autonomic Research",
issn = "0959-9851",
publisher = "D. Steinkopff-Verlag",
number = "1",

}

TY - JOUR

T1 - Optimizing clinical trial design for multiple system atrophy

T2 - Lessons from the rifampicin study

AU - Singer, Wolfgang

AU - Low, Phillip Anson

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by autonomic failure and parkinsonism/ataxia; no treatment exists to slow disease progression. A number of factors have prevented or compromised trials targeting disease modification. A major hurdle has been uncertainty about the number of patients needed to achieve adequate power. Information based on natural history studies suggested such numbers to be so large that only international multi-center models seemed feasible. When designing the rifampicin trial in MSA we sought to identify and apply strategies that would improve power and reduce the number needed to treat to allow for an oligocenter approach. Strategies included: (1) inclusion/exclusion criteria designed to enroll patients with relatively early, actively progressing disease; (2) minimizing dropouts; (3) pre-defined interim analysis; and (4) approaches to reduce scoring variability. The model allowed for the number needed to treat to be only 50 patients per treatment arm. Ten selected sites managed to reach the recruitment goal within 12 months. The dropout rate was less than 10 %, and the goal of enrolling patients with actively progressing disease was accomplished as reflected by the progression rate in the placebo group. Data from this unfortunately negative trial can now be effectively used to more realistically power future trials. A number of ways to further improve trial design and feasibility have been identified and include rigorous site selection and training, designated primary site investigators, improved error trapping, early site visits, remedial training, and future biomarkers for earlier diagnosis and tracking of disease progression.

AB - Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by autonomic failure and parkinsonism/ataxia; no treatment exists to slow disease progression. A number of factors have prevented or compromised trials targeting disease modification. A major hurdle has been uncertainty about the number of patients needed to achieve adequate power. Information based on natural history studies suggested such numbers to be so large that only international multi-center models seemed feasible. When designing the rifampicin trial in MSA we sought to identify and apply strategies that would improve power and reduce the number needed to treat to allow for an oligocenter approach. Strategies included: (1) inclusion/exclusion criteria designed to enroll patients with relatively early, actively progressing disease; (2) minimizing dropouts; (3) pre-defined interim analysis; and (4) approaches to reduce scoring variability. The model allowed for the number needed to treat to be only 50 patients per treatment arm. Ten selected sites managed to reach the recruitment goal within 12 months. The dropout rate was less than 10 %, and the goal of enrolling patients with actively progressing disease was accomplished as reflected by the progression rate in the placebo group. Data from this unfortunately negative trial can now be effectively used to more realistically power future trials. A number of ways to further improve trial design and feasibility have been identified and include rigorous site selection and training, designated primary site investigators, improved error trapping, early site visits, remedial training, and future biomarkers for earlier diagnosis and tracking of disease progression.

KW - Multiple system atrophy

KW - Rifampicin

KW - Trial design

UR - http://www.scopus.com/inward/record.url?scp=84940005436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940005436&partnerID=8YFLogxK

U2 - 10.1007/s10286-015-0281-2

DO - 10.1007/s10286-015-0281-2

M3 - Article

VL - 25

SP - 47

EP - 52

JO - Clinical Autonomic Research

JF - Clinical Autonomic Research

SN - 0959-9851

IS - 1

ER -